MCID: OCL022
MIFTS: 50

Ocular Melanoma malady

Categories: Rare diseases, Cancer diseases, Neuronal diseases, Eye diseases, Skin diseases

Aliases & Classifications for Ocular Melanoma

About this section

Aliases & Descriptions for Ocular Melanoma:

Name: Ocular Melanoma 10 45 47 12
Intraocular Melanoma 10 45 24
Uveal Melanoma 45 65
Malignant Melanoma of Eye 65
 
Melanoma of the Uvea 45
Melanoma of Eye 10
Eye Melanoma 10

Classifications:



External Ids:

Disease Ontology10 DOID:1752
UMLS65 C0558356

Summaries for Ocular Melanoma

About this section
NIH Rare Diseases:45 Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract.  the uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common.  each manifests with different clinical features and symptoms. treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors.  last updated: 11/29/2010

MalaCards based summary: Ocular Melanoma, also known as intraocular melanoma, is related to aspiration pneumonitis and molluscum contagiosum. An important gene associated with Ocular Melanoma is MC1R (Melanocortin 1 Receptor), and among its related pathways are Melanocyte Development and Pigmentation and Bladder cancer. Affiliated tissues include the eye, eye and liver, and related mouse phenotypes are pigmentation and liver/biliary system.

Disease Ontology:10 An ocular cancer that has material basis in melanocytes and is located in the eye.

Related Diseases for Ocular Melanoma

About this section

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 290)
idRelated DiseaseScoreTop Affiliating Genes
1aspiration pneumonitis29.8CDKN2A, IL2
2molluscum contagiosum29.7CDKN2A, MC1R
3choroid spindle cell melanoma29.0BAP1, CDKN2A, KIT, MC1R, NRAS, PLG
4uveal melanoma12.7
5posterior uveal melanoma12.6
6mixed cell uveal melanoma12.5
7necrotic uveal melanoma12.5
8intraocular mixed cell type melanoma11.5
9uveal epithelioid cell melanoma11.5
10tumor predisposition syndrome10.7
11ciliary body spindle cell melanoma10.5
12iris spindle cell melanoma10.5
13partial of retinal vein occlusion10.3BAP1, BRCA2
14balanitis10.3CDKN2A, IL2
15malignant epithelial mesothelioma10.3BAP1, CDKN2A
16primary effusion lymphoma10.3CDKN2A, IL2
17retinal drusen10.3CDKN2A, IL2
18ureterolithiasis10.3IL2, KIT
19rhinitis10.3IL2, KIT
20arteriosclerosis obliterans10.3BAP1, CDKN2A
21vulvar alveolar soft part sarcoma10.3BRCA2, CDKN2A
22balloon cell malignant melanoma10.3BRCA2, CDKN2A
23spinal meninges cancer10.2BRCA2, CDKN2A
24giant ganglionic hyperplasia10.2MC1R, NRAS
25lymphatic system cancer10.2BRCA2, CDKN2A
26benign mesothelioma10.2CDKN2A, KIT
27follicular basal cell carcinoma10.2CDKN2A, KIT
28neuronitis10.2
29mixed liposarcoma10.2CDKN2A, KIT
30ovary leiomyosarcoma10.2CDKN2A, KIT
31diffuse cutaneous mastocytosis10.2IL2, KIT
32prostatitis10.1
33endotheliitis10.1
34familial short qt syndrome10.1BAP1, CDKN2A
35vascular dementia10.1BRCA2, CDKN2A
36bacterial exanthem10.1IL2, NRAS
37osteoclast-like giant cell neoplasm of the pancreas10.1BRCA2, NRAS
38cervical large cell neuroendocrine carcinoma10.1CDKN2A, KIT
39gastrointestinal carcinoma10.1CDKN2A, NRAS
40benign mesenchymoma10.1CDKN2A, NRAS
41skin epithelioid hemangioma10.1IL2, PLG
42mucosal melanoma10.1KIT, NRAS
43prostate cancer10.1
44hepatitis10.1
45leukemia10.1
46neuropathy10.1
47eccrine papillary adenocarcinoma10.1KIT, NRAS
48fibrosarcoma10.1CDKN2A, KIT
49gastrointestinal neuroendocrine tumor10.1CDKN2A, NRAS
50allescheriosis10.1MC1R, PLG

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to ocular melanoma

Symptoms for Ocular Melanoma

About this section

Drugs & Therapeutics for Ocular Melanoma

About this section

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 241)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
TriamcinoloneapprovedPhase 4, Phase 2, Phase 3448124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Allernaze
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
MLS000028542
MLS001066543
 
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone Acetonide
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Trianex
Triatex
Tricortale
Triderm
Triesence
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
2
RanibizumabapprovedPhase 4, Phase 2, Phase 3, Phase 1460347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2
3Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 110422
4Angiogenesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 13688
5triamcinolone acetonidePhase 4, Phase 2, Phase 3448
6Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 19988
7Triamcinolone hexacetonidePhase 4, Phase 2, Phase 3448
8Triamcinolone diacetatePhase 4, Phase 2, Phase 3448
9Angiogenesis Modulating AgentsPhase 4, Phase 2, Phase 3, Phase 13611
10HormonesPhase 4, Phase 2, Phase 3, Phase 111748
11Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 18478
12Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018483
13glucocorticoidsPhase 4, Phase 2, Phase 33896
14Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 110002
15
PaclitaxelapprovedPhase 3, Phase 2, Phase 1262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
16
Epoetin alfaapprovedPhase 3626113427-24-0
Synonyms:
Epogen
 
Erythropoietin precursor
Procrit
17
Methylphenidateapproved, investigationalPhase 3364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
18
Dacarbazineapproved, investigationalPhase 3, Phase 2, Phase 14114342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
19
Morphineapproved, investigationalPhase 385557-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
Infumorph
 
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morphine
nchembio.317-comp1
nchembio.64-comp1
20
AldesleukinapprovedPhase 3, Phase 1, Phase 238785898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
21
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
22
Sorafenibapproved, investigationalPhase 3, Phase 2, Phase 1671284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib Tosylate
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
23
MelphalanapprovedPhase 3, Phase 2685148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
Levofalan
 
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan Hydrochloride
Melphalan [USAN:INN:BAN:JAN]
Melphalan hydrochloride
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
24
CisplatinapprovedPhase 3, Phase 1, Phase 2254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
25
CarboplatinapprovedPhase 3, Phase 2, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
26
NivolumabapprovedPhase 2, Phase 3, Phase 1198946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
27PembrolizumabapprovedPhase 3, Phase 2, Phase 1, Phase 02881374853-91-4
28
Folic Acidapproved, nutraceuticalPhase 3292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
29
Niacinapproved, investigational, nutraceuticalPhase 336159-67-6938
Synonyms:
3-Carboxylpyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
3-carboxypyridine
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Akotin
Anti-pellagra vitamin
Apelagrin
Daskil
Efacin
Enduracin
Linic
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacine
Niacor
Niaspan
Niaspan ER
Nicacid
Nicamin
 
Nicangin
Nico-Span
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
Nicotinate
Nicotinic Acid
Nicotinic acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
PP Factor
Pellagra preventive factor
Pellagrin
Pelonin
Pyridine-beta-carboxylic acid
Slo-niacin
Vitamin B3
Wampocap
beta-Pyridinecarboxylic acid
pyridine-β-carboxylic acid
β-pyridinecarboxylic acid
30
FotemustineexperimentalPhase 3, Phase 21046936889
Synonyms:
(+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate
 
Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate
Fotemustina
Fotemustinum
31Trace ElementsPhase 3, Phase 1, Phase 23900
32Protein Kinase InhibitorsPhase 3, Phase 2, Phase 13162
33Nicotinic AcidsPhase 3361
34ImmunoglobulinsPhase 3, Phase 2, Phase 1, Phase 04477
35Interferon-alphaPhase 3, Phase 21028
36interferonsPhase 3, Phase 2, Phase 11930
37Antibodies, MonoclonalPhase 3, Phase 2, Phase 1, Phase 02413
38AntibodiesPhase 3, Phase 2, Phase 1, Phase 04477
39Vitamin B ComplexPhase 32847
40VitaminsPhase 3, Phase 1, Phase 23857
41Tubulin ModulatorsPhase 3, Phase 2, Phase 14279
42MicronutrientsPhase 3, Phase 1, Phase 23901
43Central Nervous System DepressantsPhase 3, Phase 2, Phase 110016
44Anesthetics, IntravenousPhase 31943
45NarcoticsPhase 3, Phase 1, Phase 22709
46pancreatic polypeptidePhase 3, Phase 2, Phase 120
47Peripheral Nervous System AgentsPhase 3, Phase 2, Phase 118510
48AnestheticsPhase 3, Phase 27385
49Analgesics, OpioidPhase 3, Phase 1, Phase 22304
50Alkylating AgentsPhase 3, Phase 1, Phase 23582

Interventional clinical trials:

(show top 50)    (show all 312)
idNameStatusNCT IDPhase
1Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque RadiotherapyActive, not recruitingNCT00540930Phase 4
2TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam TherapyActive, not recruitingNCT02379000Phase 4
3Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to MelanomaCompletedNCT00324727Phase 3
4Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
5An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedNCT01368276Phase 3
6Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced MelanomaCompletedNCT01989572Phase 3
7Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaCompletedNCT00019682Phase 3
8Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00110019Phase 3
9Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV MelanomaCompletedNCT00072124Phase 3
10Evaluation of Pigmented Skin Lesions With MelaFind(R) SystemCompletedNCT00434057Phase 3
11E-MOSAIC Electronic Tool to Monitor SymptomsCompletedNCT00477919Phase 3
12Dendritic Cells Plus Autologous Tumor RNA in Uveal MelanomaRecruitingNCT01983748Phase 3
13The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver MetastasesRecruitingNCT01785316Phase 3
14Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular MelanomaRecruitingNCT02678572Phase 3
15Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II MelanomaRecruitingNCT01826864Phase 3
16Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryRecruitingNCT01274338Phase 3
17Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryRecruitingNCT02339571Phase 2, Phase 3
18Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)Active, not recruitingNCT01974752Phase 3
19Collaborative Ocular Melanoma Study (COMS)Active, not recruitingNCT00000124Phase 3
20Vaccine Therapy in Treating Patients With Primary Stage II MelanomaActive, not recruitingNCT00005052Phase 3
21Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation TherapyActive, not recruitingNCT01223248Phase 3
22Treatment Of Radiation Retinopathy TrialNot yet recruitingNCT00811200Phase 2, Phase 3
23Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye MelanomaTerminatedNCT00110123Phase 3
24Vaccine Therapy in Treating Patients With Melanoma of the EyeTerminatedNCT00036816Phase 3
25A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic MelanomaTerminatedNCT01006252Phase 3
26High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III MelanomaTerminatedNCT00003641Phase 3
27Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone MetastasesTerminatedNCT00540969Phase 3
28Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain MetastasesTerminatedNCT00581113Phase 3
29High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII MelanomaWithdrawnNCT00447356Phase 3
30Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By SurgeryCompletedNCT00738361Phase 2
31Safety and Efficacy of Marqibo in Metastatic Malignant Uveal MelanomaCompletedNCT00506142Phase 2
32Cixutumumab in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT01413191Phase 2
33Vaccine Therapy in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT00020475Phase 2
34Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the EyeCompletedNCT00329641Phase 2
35Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaCompletedNCT00084656Phase 2
36Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSFCompletedNCT00661622Phase 2
37Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV MelanomaCompletedNCT00089219Phase 1, Phase 2
38Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00089206Phase 2
39PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic MelanomaCompletedNCT00238329Phase 2
40Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00005815Phase 1, Phase 2
41Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00334776Phase 2
42Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003339Phase 2
43Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye MelanomaCompletedNCT00003802Phase 2
44Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00058279Phase 1, Phase 2
45Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV MelanomaCompletedNCT00072345Phase 2
46Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00027742Phase 2
47Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00032045Phase 2
48Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaCompletedNCT00031733Phase 2
49Vaccine Therapy in Treating Patients With Stage IIC-IV MelanomaCompletedNCT00085189Phase 2
50Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by SurgeryCompletedNCT01533948Phase 2

Search NIH Clinical Center for Ocular Melanoma

Genetic Tests for Ocular Melanoma

About this section

Anatomical Context for Ocular Melanoma

About this section

MalaCards organs/tissues related to Ocular Melanoma:

33
Eye, Liver, T cells, Skin, Bone, Breast, Lymph node

FMA organs/tissues related to Ocular Melanoma:

16
The eye

Animal Models for Ocular Melanoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Ocular Melanoma:

38 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.2CDKN2A, KIT, MC1R, NRAS
2MP:00053708.5CDKN2A, IL2, KIT, NRAS, PLG
3MP:00030128.4BAP1, CDKN2A, IL2, KIT, MC1R, NRAS
4MP:00107718.2BRCA2, CDKN2A, KIT, MC1R, NRAS, PLG
5MP:00053818.0BRCA2, CDKN2A, IL2, KIT, NRAS, PLG
6MP:00053797.7BRCA2, CDKN2A, CIITA, IL2, KIT, NRAS
7MP:00053857.6BAP1, CDKN2A, IL2, KIT, NRAS, PLG
8MP:00020067.5BAP1, BRCA2, CDKN2A, IL2, KIT, MC1R
9MP:00053847.4BAP1, BRCA2, CDKN2A, IL2, KIT, MC1R
10MP:00053787.2BAP1, BRCA2, CDKN2A, IL2, KIT, MC1R
11MP:00053767.0BAP1, BRCA2, CDKN2A, CIITA, IL2, KIT
12MP:00053976.9BAP1, BRCA2, CDKN2A, CIITA, IL2, KIT
13MP:00053876.6BAP1, BRCA2, CDKN2A, CIITA, IL2, KIT

Publications for Ocular Melanoma

About this section

Articles related to Ocular Melanoma:

(show top 50)    (show all 316)
idTitleAuthorsYear
1
Brain and behavior in 48, XXYY syndrome. (26106537)
2015
2
A 13-year retrospective study evaluating the efficacy of using air-fluidised beds for toxic epidermal necrolysis patients. (25817418)
2015
3
Angiotensin-(1-7) upregulates expression of adenosine triphosphate-binding cassette transporter A1 and adenosine triphosphate-binding cassette transporter G1 through the Mas receptor through the liver X receptor alpha signalling pathway in THP-1 macrophages treated with angiotensin-II. (25225013)
2014
4
Late diagnosis of celiac disease in an asymptomatic infant with growth failure. (24428915)
2014
5
Analysis of ornithine transcarbamylase gene mutations in three boys affected with late-onset ornithine transcarbamylase deficiency]. (25297582)
2014
6
Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. (24419221)
2014
7
Prenatal ultrasonography and postnatal follow-up of a case of McKusick-Kaufman syndrome. (25017277)
2014
8
Dual epidemics of syphilis and methamphetamine use among drug users in Shandong Province of China. (23394142)
2013
9
C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: a minireview. (23842006)
2013
10
Diffusion analysis with triexponential function in liver cirrhosis. (23239543)
2013
11
Cardiovascular MR imaging findings of total anomalous pulmonary venous connection to the portal vein in a patient with right atrial isomerism. (23238601)
2012
12
TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. (22031828)
2011
13
TGF-I^1, EGF and FGF4 synergistically induce differentiation of the seminoma cell line TCam-2 into a cell type resembling mixed non-seminoma. (21649665)
2011
14
Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. (21216463)
2011
15
No significance of the COMT val158met polymorphism in restless legs syndrome. (20184941)
2010
16
Increase brain lactate in hepatic encephalopathy: cause or consequence? (20600436)
2010
17
IgE, mast cells, basophils, and eosinophils. (20176269)
2010
18
Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. (20804692)
2010
19
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. (20157014)
2010
20
Identification of Sp1-elements in the promoter region of human homeobox gene NKX3.1. (19263243)
2009
21
IGFBP-3 and IGFBP-5 associate with the cell binding domain (CBD) of fibronectin. (19236847)
2009
22
Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. (17955299)
2008
23
Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. (18642443)
2008
24
Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. (18371109)
2008
25
MDR1 polymorphisms effect cyclosporine AUC0-4 values in BehAset's disease patients. (19668484)
2007
26
Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. (17117487)
2007
27
Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. (17702744)
2007
28
Familial lecithin-cholesterol acyltransferase (LCAT) deficiency]. (17824097)
2007
29
beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. (16815314)
2006
30
Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? (16500317)
2006
31
Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. (15785246)
2005
32
Molecular basis of adrenal insufficiency. (15817507)
2005
33
Outpatient management of phimosis following newborn circumcision. (12771793)
2003
34
Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. (11591326)
2001
35
Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. (10970869)
2000
36
C-reactive protein and serum amyloid A protein in neonatal infections. (10879591)
2000
37
Differential interactions of the growth factor receptor-bound protein 2 N-SH3 domain with son of sevenless and dynamin. Potential role in the Ras-dependent signaling pathway. (9478994)
1998
38
Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study. (10420069)
1998
39
Acquired isolated factor VII deficiency during sepsis. (9212352)
1997
40
Excess cyclovergence in patients with intermittent exotropia. (8560798)
1995
41
A new human slow skeletal troponin T (TnTs) mRNA isoform derived from alternative splicing of a single gene. (8135831)
1994
42
Different arachidonate and palmitate binding capacities of the human red cell membrane. (7707348)
1994
43
The IGF-II receptor system: a G protein-linked mechanism. (8398119)
1993
44
Outbreak of infection in two UK hospitals caused by a strain of Klebsiella pneumoniae resistant to cefotaxime and ceftazidime. (1348768)
1992
45
Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate. (1942080)
1991
46
Injuries to the talus-neck fractures and osteochondral lesions (osteochondritis dissecans). (1875012)
1991
47
Response of human immunodeficiency virus long terminal repeat to growth factors and hormones. (2241099)
1990
48
AB0 blood group incompatibility and inbreeding effects: evidence for an interaction. (3972416)
1985
49
Sensitization to house dust, bacteria and fungi in byssinosis. (4984397)
1969
50
Heparin therapy in fulminant meningococcemia. (5804192)
1969

Variations for Ocular Melanoma

About this section

Expression for genes affiliated with Ocular Melanoma

About this section
Search GEO for disease gene expression data for Ocular Melanoma.

Pathways for genes affiliated with Ocular Melanoma

About this section

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.7KIT, MC1R
29.5CDKN2A, NRAS
3
Show member pathways
9.2BRCA2, CDKN2A, NRAS
49.2CDKN2A, IL2, NRAS
58.8BRCA2, CDKN2A, KIT, NRAS

GO Terms for genes affiliated with Ocular Melanoma

About this section

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.2IL2, KIT
2T cell differentiationGO:003021710.2IL2, KIT
3somatic stem cell divisionGO:004810310.1CDKN2A, KIT
4fibroblast growth factor receptor signaling pathwayGO:00085439.4IL2, KIT, NRAS
5MAPK cascadeGO:00001659.3IL2, KIT, NRAS
6activation of MAPKK activityGO:00001869.2IL2, KIT, NRAS
7vascular endothelial growth factor receptor signaling pathwayGO:00480109.1IL2, KIT, NRAS
8insulin receptor signaling pathwayGO:00082869.0IL2, KIT, NRAS
9positive regulation of transcription from RNA polymerase II promoterGO:00459448.9CDKN2A, CIITA, IL2, MC1R

Sources for Ocular Melanoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet